A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects

Trial Profile

A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Apr 2009

At a glance

  • Drugs Recombinant protective antigen anthrax vaccine Altimmune (Primary)
  • Indications Anthrax
  • Focus Adverse reactions
  • Sponsors PharmAthene
  • Most Recent Events

    • 28 Apr 2009 Results were presented at the 12th Annual Conference on Vaccine Research, according to a PharmAthene media release.
    • 24 Feb 2009 Results were presented at the 7th Annual ASM Biodefence meeting, according to a PharmAthene media release.
    • 14 Sep 2008 Actual patient number (415) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top